Kevin Coyle
Interventional Pain Medicine · Brunswick, GANPI 1891883765
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 91.2% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $13,277 and has fallen 89.9% since, to $1,340 in 2025.
Across 300 payments — averaging $61.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$17K
- Collegium Pharmaceutical, Inc.$474
- Scilex Pharmaceuticals Inc.$184
- Saluda Medical Americas, Inc.$180
- Kowa Pharmaceuticals America, Inc.$165
- Si-bone, Inc.$137
- plus $489 from 21 others
What the payments were for
- Speaking & faculty fees$10,57557%
- Travel & lodging$1,4458%
- Food & beverage$6,53935%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 219 | $16,931 |
| Collegium Pharmaceutical, Inc. | 28 | $474 |
| Scilex Pharmaceuticals Inc. | 10 | $184 |
| Saluda Medical Americas, Inc. | 5 | $180 |
| Kowa Pharmaceuticals America, Inc. | 1 | $165 |
| Si-bone, Inc. | 3 | $137 |
| Biodelivery Sciences International, Inc. | 5 | $71 |
| Pfizer | 3 | $52 |
| Bioventus LLC | 2 | $34 |
| AstraZeneca | 3 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Sentynl Therapeutics, Inc. | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Forte Bio-pharma LLC | 2 | $16 |
| Acelrx Pharmaceuticals, Inc. | 1 | $16 |
| AbbVie | 1 | $16 |
| Amgen | 1 | $16 |
| Virtus Pharmaceuticals LLC | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
| Curonix LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
| Shionogi Inc | 1 | $13 |
| Baudax Bio Inc. | 1 | $13 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPECTRA WAVEWRITER$11,199
- GENERAL - THERAPIES$1,385
- WaveWriter Alpha Prime 16$359
- WAVEWRITER ALPHA$178
- Seglentis$165
- GENERAL PAIN MANAGEMENT$150
How this compares
$18,559 in reported general payments places this provider in the 85th percentile of 129 interventional pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nucynta ErTapentadol Hcl | 154 | $164,077 |
| NucyntaTapentadol Hcl | 146 | $150,413 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,345 | $48,283 |
| Hysingla ErHydrocodone Bitartrate | 41 | $27,515 |
| Buprenorphine | 72 | $19,532 |
| BelbucaBuprenorphine Hcl | 27 | $11,565 |
| Morphine Sulfate ErMorphine Sulfate | 172 | $4,893 |
| Methadone Hcl | 173 | $3,028 |
| Tramadol Hcl ErTramadol Hcl | 61 | $2,730 |
| Pregabalin | 198 | $2,686 |
| Lidocaine | 16 | $1,948 |
| Tramadol Hcl | 283 | $1,701 |
| Morphine Sulfate | 42 | $917 |
| Baclofen | 77 | $809 |
| Tizanidine Hcl | 63 | $643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er, Nucynta, Belbuca | $474 | $326,055327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 129 interventional pain medicine providers in Georgia.
Other interventional pain medicine in Brunswick
- Emmanuel GageBrunswick$602K
- Christopher BovinetBrunswick$338K
- Jordan TateJasper$540K
- David RosenfeldCovington$249K
- Nathan NeufeldNewnan$171K
- Ryan BudwanyLawrenceville$123K
- Alexandra MoreiraAtlanta$79K
- Sushanth BodaNewnan$55K
- Christopher AndrianoStockbridge$41K
- Guensley DelvaWaycross$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.